IO Frontiers World 2019


Cedrik Britten

Dr Cedrik Britten

Head Cellular Therapy, Immuno-Oncology,, GlaxoSmithKline

Dr. Cedrik Britten is the Head of Cell Therapy within GSK’s Immuno-Oncology and Combinations Unit. At GSK he heads a group developing innovative immunotherapies for treatment of cancer patients with high unmet medical need that are based on immune-receptor engineered immune-cells. Dr. Britten is a physician and immunologist who has worked in Tumour–Immunology since 1998. Prior to joining GSK he was Vice President R&D at BioNTech RNA Pharmaceuticals developing highly personalized immunotherapies. He has also been initiating and leading field-serving working groups within the non-for profit Association for Cancer Immunotherapy since 2003 with focus on novel biomarkers, regularity framework for novel personalized medicine approaches and commercialisation of technologies.


  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy